Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer
in Endocrine-Related Cancer
Authors: Rayzel C Fernandes 1 , 2 , Theresa E Hickey 1 , Wayne D Tilley 1 , 2 and Luke A Selth 1 , 2
View Less
0 Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia 1 Freemasons Foundation Centre for Men’s Health, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia
Correspondence should be addressed to L A Selth: luke.selth@adelaide.edu.au
DOI: https://doi.org/10.1530/ERC-18-0571
Page(s): R237–R257
Volume/Issue: Volume 26: Issue 5
Article Type: Review Article
Online Publication Date: May 2019
Copyright: © 2019 Society for Endocrinology 2019
Free access
Download PDF
Check for updates
Citation Alert Citation Alerts
Get Permissions
Abstract/Excerpt
Full Text
PDF
Abstract
The androgen receptor (AR) is a ligand-activated transcription factor that drives prostate cancer. Since therapies that target the AR are the mainstay treatment for men with metastatic disease, it is essential to understand the molecular mechanisms underlying oncogenic AR signaling in the prostate. miRNAs are small, non-coding regulators of gene expression that play a key role in prostate cancer and are increasingly recognized as targets or modulators of the AR signaling axis. In this review, we examine the regulation of AR signaling by miRNAs and vice versa and discuss how this interplay influences prostate cancer growth, metastasis and resistance to therapy. Finally, we explore the potential clinical applications of miRNAs implicated in the regulation of AR signaling in this prevalent hormone-driven disease.